MedTrace Logo

Preemptive Chlorepheniramine Maleate Reducing Postoperative Agitation

NCT04293081 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-08-11

No results posted yet for this study

Summary

The aim of the study is to identify the role of preoperative chlorepheniramine maleate on alleviating or reducing the severity of postoperative agitation following FESS procedures.

Conditions

  • Agitated; State, Acute Reaction to Stress

Interventions

DRUG

Preemptive chlorepheniramine maleate intravenous injection

Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes

DRUG

normal saline

participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-16
Primary Completion
2019-05-31
Completion
2019-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04293081 on ClinicalTrials.gov